Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Moodys

Last Updated: November 29, 2022

Details for Patent: 6,858,618


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,858,618 protect, and when does it expire?

Patent 6,858,618 protects CRESTOR and is included in one NDA.

Protection for CRESTOR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty-four countries.

Summary for Patent: 6,858,618
Title: Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Abstract:The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
Inventor(s): Raza; Ali (Cheshire, GB), Hutchinson; Howard Gerard (Delaware, DE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/432,402
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,858,618

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipr CRESTOR rosuvastatin calcium TABLET;ORAL 021366-002 Aug 12, 2003 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ipr CRESTOR rosuvastatin calcium TABLET;ORAL 021366-003 Aug 12, 2003 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ipr CRESTOR rosuvastatin calcium TABLET;ORAL 021366-004 Aug 12, 2003 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ipr CRESTOR rosuvastatin calcium TABLET;ORAL 021366-005 Aug 12, 2003 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,858,618

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0028429Nov 22, 2000
PCT Information
PCT FiledNovember 16, 2001PCT Application Number:PCT/GB01/05041
PCT Publication Date:May 30, 2002PCT Publication Number: WO02/41895

International Family Members for US Patent 6,858,618

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 031766 See Plans and Pricing
Austria 394103 See Plans and Pricing
Australia 1416502 See Plans and Pricing
Australia 2002214165 See Plans and Pricing
Bulgaria 107811 See Plans and Pricing
Bulgaria 66009 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
Merck
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.